Business Description
Rallybio Corp
NAICS : 541714
SIC : 2834
ISIN : US75120L1008
Description
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 326.69 | |||||
| Equity-to-Asset | 0.9 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -20.4 | |||||
| 3-Year EPS without NRI Growth Rate | -15.7 | |||||
| 3-Year FCF Growth Rate | -14.3 | |||||
| 3-Year Book Growth Rate | -22.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.66 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.34 | |||||
| 9-Day RSI | 47.09 | |||||
| 14-Day RSI | 49.44 | |||||
| 3-1 Month Momentum % | -3.54 | |||||
| 6-1 Month Momentum % | -34.34 | |||||
| 12-1 Month Momentum % | -63.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.55 | |||||
| Quick Ratio | 9.55 | |||||
| Cash Ratio | 9.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.4 | |||||
| Shareholder Yield % | 0.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11705.69 | |||||
| Net Margin % | -11199.5 | |||||
| FCF Margin % | -8539.3 | |||||
| ROE % | -71.28 | |||||
| ROA % | -64.45 | |||||
| ROIC % | -1411.46 | |||||
| 3-Year ROIIC % | -1482.29 | |||||
| ROC (Joel Greenblatt) % | -7958.16 | |||||
| ROCE % | -74.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 80 | |||||
| PB Ratio | 0.66 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 0.41 | |||||
| EV-to-Forward-EBIT | -1.14 | |||||
| EV-to-EBITDA | 0.41 | |||||
| EV-to-Revenue | -47.56 | |||||
| EV-to-FCF | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 0.64 | |||||
| Price-to-Net-Cash | 0.67 | |||||
| Earnings Yield (Greenblatt) % | 243.9 | |||||
| FCF Yield % | -109.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLYB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rallybio Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.598 | ||
| EPS (TTM) ($) | -1.59 | ||
| Beta | -1.48 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 101.12 | ||
| 14-Day RSI | 49.44 | ||
| 14-Day ATR ($) | 0.080839 | ||
| 20-Day SMA ($) | 1.07325 | ||
| 12-1 Month Momentum % | -63.3 | ||
| 52-Week Range ($) | 0.95 - 3.46 | ||
| Shares Outstanding (Mil) | 41.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rallybio Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rallybio Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rallybio Corp Frequently Asked Questions
What is Rallybio Corp(RLYB)'s stock price today?
The current price of RLYB is $1.08. The 52 week high of RLYB is $3.46 and 52 week low is $0.95.
When is next earnings date of Rallybio Corp(RLYB)?
The next earnings date of Rallybio Corp(RLYB) is 2025-03-12 Est..
Does Rallybio Corp(RLYB) pay dividends? If so, how much?
Rallybio Corp(RLYB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers